Gilead Seeks Deals as U.S. Hepatitis C Sales May FlattenBy
Drugmaker announces $12 billion added to share repurchase
Hepatitis C drugs sell $4.89 billion in fourth quarter
Gilead Sciences Inc. expects U.S. use of its blockbuster hepatitis C treatment to be flat or stable this year as the franchise faces new competition from other drugmakers. The biotechnology firm is on the lookout for acquisition opportunities to sustain growth, executives said.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.